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Abstract: Clonal heterogeneity detected by karyotyping is a biomarker associated with adverse 
prognosis in acute myeloid leukemia (AML). Constitutive activation of the phosphatidylinositol-3-
kinase-Akt-mechanistic target of rapamycin (PI3K-Akt-mTOR) pathway is present in AML cells, 
and this pathway integrates signaling from several upstream receptors/mediators. We suggest that 
this pathway reflects biologically important clonal heterogeneity. We investigated constitutive 
PI3K-Akt-mTOR pathway activation in primary human AML cells derived from 114 patients, 
together with 18 pathway mediators. The cohort included patients with normal karyotype or single 
karyotype abnormalities and with an expected heterogeneity of molecular genetic abnormalities. 
Clonal heterogeneity reflected as pathway mediator heterogeneity was detected for 49 patients. 
Global gene expression profiles of AML cell populations with and without clonal heterogeneity 
differed with regard to expression of ectopic olfactory receptors (a subset of G-protein coupled 
receptors) and proteins involved in G-protein coupled receptor signaling. Finally, the presence of 
clonal heterogeneity was associated with adverse prognosis for patients receiving intensive 
antileukemic treatment. The clonal heterogeneity as reflected in the activation status of selected 
mediators in the PI3K-Akt-mTOR pathway was associated with a different gene expression profile 
and had an independent prognostic impact. Biological heterogeneity reflected in the intracellular 
signaling status should be further investigated as a prognostic biomarker in human AML. 
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1. Introduction 
Acute myeloid leukemia (AML) is a heterogeneous malignancy characterized by proliferating 
myeloblasts in the bone marrow [1–3]. Abnormal or constitutive signaling through intracellular 
pathways is often observed in the leukemic cells, including the phosphatidylinositol-3-kinase-Akt-
mechanistic target of rapamycin (PI3K-Akt-mTOR) pathway that seems to be important both in 
normal and leukemic hematopoiesis [4–6]. Such abnormal signaling can be initiated by various 
mechanisms, e.g., various oncogenes or mutated receptor tyrosine kinases, cell adhesion molecules, 
G-protein-coupled receptors (GPCR) or other cytokine receptors. 
Primary AML cell populations may include various subclones at the time of diagnosis, and 
relapse can occur due to regrowth of the originally dominating clone, a subclone detectable at the 
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time of first diagnosis, or a new clone derived either from the original clone or from remaining 
preleukemic stem cells [7,8]. Detection of remaining leukemic cells with cytogenetic abnormalities at 
the time of allogeneic stem cell transplantation is associated with an adverse prognostic impact even 
when residual disease cannot be detected by flow cytometry, and morphological examination 
confirms that the patient is still in complete hematological remission [8]. One possible explanation 
for such a discrepancy may be the detection of a remaining minor subclone with a different 
immunophenotype compared with the dominating clone at the time of diagnosis [7]. The detection 
of subclones (i.e., clonal heterogeneity) based on karyotyping at the time of initial diagnosis is an 
independent adverse prognostic factor [9]. However, karyotyping for detection of clonal 
heterogeneity has several limitations as it is not a sensitive methodological approach and it cannot 
be used to detect heterogeneity for the majority of patients with normal karyotype or single 
cytogenetic abnormalities. 
Clonal heterogeneity of AML cell populations can also be detected by flow cytometric analysis 
of constitutively activated intracellular signaling pathways, and this may therefore be an alternative 
methodological strategy [10] that can be used also for evaluation of the large group of patients with 
normal karyotype. Such analyses may also reflect a functional heterogeneity caused by driving 
mutations and thereby reflect characteristics that are important for leukemogenesis and/or 
chemosensitivity. In our present study, we therefore investigated how clonal heterogeneity is 
reflected in the activation status of the PI3K-Akt-mTOR pathway. This pathway was chosen because 
(i) it is usually activated in primary human AML cells; (ii) integrates signaling from a wide range of 
upstream mediators/receptors; (iii) shows crosstalk with and thereby also reflects the activation status 
of parallel intracellular pathways; and (iv) targets a wide range of downstream mediators that are 
important for essential cellular processes e.g., regulation of energy metabolism, gene transcription, 
protein synthesis, induction of apoptosis, and cellular communication [4,6,11]. In this context, we 
have therefore investigated samples from a group of 114 unselected patients to clarify whether 
analysis of constitutive PI3K-Akt-mTOR signaling can be used to detect clonal heterogeneity, 
whether such heterogeneity is a biomarker associated with any clinical or biological patient 
characteristics, and whether clonal heterogeneity has an independent prognostic impact. 
2. Results 
2.1. Clonal AML Cell Heterogeneity Reflected by PI3K-Akt-mTOR Signaling Is Seen for a Subset of Patients 
In our flow cytometric analysis, we first identified the viable AML cells; this gating strategy is 
shown in Figure S1. The viable cell population was thereafter analyzed for expression levels of 
mediators and their phosphorylation. The viability of primary cells was analyzed both immediately 
after thawing and after the incubation steps by live dead gating. The viability did not differ 
significantly when comparing these two time points. The median frequency of dead cells after the 
incubation steps was 16.3% (range 0–48%). The viability of the AML cells did not differ when 
comparing AML cell samples with and without dual leukemic cell populations. 
We investigated the 18 mediators from the PI3K-Akt-mTOR pathway in leukemic cell samples 
from 114 unselected AML patients. Dual populations were detected in samples from 49 of patients 
and these overall results are summarized in Figure 1. The flow cytometric evidence for clonal 
heterogeneity is presented more in detail in Figure S1, and it can be seen that a minor population was 
clearly separated from the main AML cell population for all the 49 patients. 
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Figure 1. Clonal heterogeneity of primary human acute myeloid leukemia (AML) cell samples; an 
overview of the 49 patients showing dual populations when investigating activation of the 
phosphatidylinositol-3-kinase-Akt-mechanistic target of rapamycin (PI3K-Akt-mTOR) pathway. The 
cells were incubated in medium alone (all patients), with insulin alone and with insulin and a 
pathway inhibitor (rapamycin, GDC-0941; only an unselected subset of patients). Dark grey means 
that dual populations were detected in all cultures with and without treatment, and light grey 
indicates detection only for some cultures. Patient samples analyzed for inhibition by mTOR inhibitor 
rapamycin and PI3K inhibitor GDC-0941 are indicated by an asterisk (*). 
For each of the 49 patients, clonal heterogeneity was detected only for some of the 18 mediators. 
Nineteen of the patients showed dual population for only one of any of the 18 mediators, 16 patients 
showed dual populations for two mediators, and dual populations for three mediators was found for 
seven patients. Thus, for the majority of these patients, dual AML cell populations were detected only 
by one or a few of the tested mediators, and dual populations for four to seven pathway mediators 
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Dual populations for mediators upstream to Akt were detected for 20 patients, whereas dual 
populations for Akt and mTOR were only detected for four of these 20 patients. Dual populations for 
mediators downstream to mTOR were detected for 10 patients. Furthermore, clonal heterogeneity 
reflected in constitutive Akt activation but not reflected by mediators upstream to Akt was found in 
17 patients. This heterogeneity reflects differences in activation alone because the total protein levels 
of Akt did not differ between cell subsets. Finally, it was uncommon for mTOR total protein level or 
phosphorylation/activation to reflect clonal heterogeneity. 
Taken together, the observations described above show that 49 out of 114 patients with clonal 
heterogeneity differ with regard to how the heterogeneity is reflected in the PI3K-Akt-mTOR 
expression/phosphorylation profile. 
The patient subsets with and without clonal heterogeneity were also compared with regard to 
their molecular genetics (i.e., analysis of 54 different mutations), morphological as well as molecular 
signs of differentiation and the overall PI3K-Akt-mTOR activation profile; though the two patient 
subsets did not show any significant differences with regard to these biological characteristics (see 
Table S1). 
2.2. Primary AML Cells Derived from Patients with and without dual PI3K-Akt-mTOR Cell Populations 
Differ in Their Global Gene Expression Profiles 
We compared the global gene expression profiles for 12 AML samples with and 27 samples 
without dual AML cell populations. A feature subset selection (FSS) analysis was performed for 
identification of the most discriminative genes between the two groups, and 1209 genes were then 
identified (i.e., p-value <0.05, see the complete gene list is included in Table S5 and Table S6). This 
criterion was chosen because AML is a highly heterogeneous disease with regard to differentiation, 
karyotype and molecular genetics [1–3]; and this can be seen from the characteristics of our present 
patient cohort (Tables 1 and 2 below, Table S1). For this reason, a relatively large number of 
differentially expressed genes will probably be needed to distinguish between patient subsets. The 
identified genes were used in a hierarchical clustering model (Pearson’s correlation distance measure 
with complete linkage; and this analysis identified two main patient subsets that corresponded to the 
patients with and without subpopulations. Furthermore, a correlation visualization with distance 
matrix displays the pairwise correlation between the 39 patients and the classification of patients into 
two main subsets corresponding to the subsets with and without subclones, respectively (Figure 2). 
Table 1. A comparison of overall survival for patients with and without dual populations based on 
the analysis of PI3K-Akt-mTOR activation. The table presents the results from univariate and adjusted 
or multivariate analyses (Cox Proportional Hazard Model). Significant p-values in the adjusted 
analysis are marked in bold. 
Covariate 
Crude Analysis Adjusted Analysis 
p-Value HR 95%-CI p-Value HR 95%-CI 
Age (per decade) <0.01 1.64 1.24–2.17 <0.01 1.69 1.22–2.36 
Subpopulation versus 
no subpopulation 
0.03 2.15 1,01–4,26 0.04 2.28 1.03–5.04 
Adverse cytogenetics 0.519 0.759 0.33–1.75 0.11 0.33 0.11–1.04 
NPM1-wt and Flt3-wt NA 1 (reference)  NA 1 (reference)  
NPM1-mutated and 
Flt3-wt 
0.92 1.62 0.58–4.56 0.693 1.24 0.42–3.75 
NPM1-wt and FLT3-
mutated 
0.21 1.86 0.71–4.92 0.03 3.88 1.18–12.71 
NPM1-mutated and 
FLT3-mutated 
0.05 2.33 1.00–5.34 0.48 1.44 0.57–3.61 
Abbreviations: CI, confidence interval; HR, hazard ratio. NPM1-wt: Nucleophosmin 1-wild type;  Flt3-wt: fms-
like tyrosine kinase 3-wild type.  
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Table 2. The biological and clinical characteristics of the 114 AML patients included in the study. 
Patient characteristics 
Age Secondary AML 
Median (years) 67 chemo 5 
Range (years) 18–87 CML 2 
  CML-RELAPSE 1 
Gender  CMML 4 
Females 49 de novo 81 
Males 65 LiFraum, chemo 1 
  MDS 8 
  MDS, AML relapse 1 
  MDS, CHEMO 1 
  Myelofibrosis 3 
  Polycytemia vera 1 
  Relapse 5 
Total 114 Relapse, chemo 1 
Cell Morphology 
FAB Classification CD34 Receptor 
M0 8 Negative (<20%) 30 
M1 28 Positive (>20%) 78 
M2 22 n.d. 6 
M4 27   
M5 21   
M7 1   










Favorable 11 Wild-type  62 
Intermediate 11 n.d. 17 
Normal 60   
n.d. 12 Flt3 mutations 
  ITD 41 
  Wild-type  55 
  n.d. 18 
The European Leukemia Net classification was used; n.d.: not determined; CML: Chronic myeloid 
leukemia; CMML:Chronic myelomonocytic leukemia; FAB: French-American-British. 
The differentially expressed genes were thereafter used to identify gene ontology terms that 
were overrepresented among the differentially expressed genes. We then selected Gene Ontology 
(GO) terms based on the criteria (i) False Discovery Rate (FDR) ad modum Benjamini <0.05 and (ii) 
p-values <0.05. Only two GO-terms were identified in each of the two analyses based on Biological 
processes or Molecular function, respectively. Based on Molecular function, the two groups G-protein 
coupled receptor signaling pathway (p = 0.0000078; 43 genes included) and Detection of chemical 
stimulus involved in sensory perception of smell (p = 0.000015; 26 genes included) were identified. 
Based on analysis of Biological processes we identified the two groups G-protein coupled receptor 
activity (p = 0.00002; 36 genes included) and Olfactory receptor activity (p = 0.000024; 26 genes 
included). The complete gene lists for each of these four GO terms are presented in Tables S2 and S3. 
None of the two patient subsets showed generally higher expression for all differentially expressed 
genes, but the two subsets differ in their pattern of high/low expressed genes. 
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Figure 2. Comparison of global gene expression profiles and gene ontology for primary human AML cells with and without clonal heterogeneity based on the analysis of 
PI3K-Akt-mTOR activation. Global gene expression profiles (GEP) were available for 39 unselected AML patients included in the study, 12 samples were derived from 
patients showing dual cell populations and 27 leukemic cell populations did not show dual cell populations. (A) A feature subset selection (FSS) was performed to identify 
the most discriminative genes between the two groups, and 1209 genes were identified (p-value <0.05). These genes were used in a hierarchical clustering model (Pearson’s 
correlation distance measure with complete linkage) demonstrating a highly discriminative expression pattern for the groups with and without subclones. (B) A correlation 
visualization with distance matrix displays the pairwise correlation between the 39 patients. Blue and green colors highlight the negative and positive correlation between 
samples. The genes found differently expressed were thereafter used to identify gene ontology terms (using the David Database for Gene Ontology) that were 
overrepresented among the genes differently expressed. A more detailed version is shown in Figure S3. 
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2.3. Detection of AML Subclones Based upon PI3K-Akt-mTOR Signaling Is Associated with Decreased 
Patient Survival 
In a recent study, karyotyping could detect clonal heterogeneity for approximately 15% of 
patients, and this heterogeneity was then associated with an adverse prognosis in patients receiving 
intensive AML therapy [9]. We therefore investigated whether detection of subclones determined by 
analysis of constitutive PI3K-Akt-mTOR activation had a similar prognostic association. In our 
present study, we investigated a large group of unselected patients that included several elderly and 
unfit patients who could not receive intensive treatment [12]. However, 44 of our patients completed 
their planned intensive induction treatment followed by at least two consolidation cycles, autologous 
or allogeneic stem cell transplantation after their first diagnosis of AML. We compared the survival 
of 17 patients with and 27 patients without subpopulations; the overall survival was significantly 
higher for patients without subpopulations (Figure 3; p = 0.027). This association between prognosis 
and heterogeneity was significant both in crude (Table 1, Cox Proportional Hazard Model, p = 0.03) 
and adjusted analyses (p = 0.04). To summarize, the previous study [9] showed that detection of clonal 
heterogeneity in patients with abnormal karyotype had an adverse prognostic impact. In our present 
study we used an alternative methodological strategy for detection of subclones independent of the 
karyotype (i.e., also including patients with normal karyotype), and we could detect an association 
between clonal heterogeneity and adverse prognosis. 
We also did an adjusted analysis of the prognostic impact of age, clonal heterogeneity, 
cytogenetics, Flt3/NPM1 status (Table 1). After correcting for these adverse factors, clonal 
heterogeneity still had a significant association with survival. 
 
Figure 3. Overall survival of patients with (17 patients) and without (27 patients) clonal heterogeneity 
when investigating PI3K-Akt-mTOR pathway activation; an analysis of 44 patients who completed 
their intensive induction treatment followed by at least two consolidation cycles, autologous or 
allogeneic stem cell transplantation after their first diagnosis of AML. 
3. Discussion 
The PI3K-Akt-mTOR pathway shows constitutive activation in human AML and is therefore 
regarded as a possible therapeutic target, but despite this, the results from initial clinical studies 
suggest that pathway inhibitors have only modest antileukemic activity [13]. Possible explanations 
for this could be that patients are heterogeneous with regard to their susceptibility [14] due to 
differences in the crosstalk with other pathway [15], or there is clonal heterogeneity with variation in 
constitutive pathway activation between leukemic subclones for individual patients [7]. In the 
present study, we used flow cytometric analysis of PI3K-Akt-mTOR activation to detect clonal 
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heterogeneity. We investigated a large group of samples derived from unselected AML patients (i.e., 
the large majority of the patients had normal karyotype or only a single cytogenetic abnormality), 
and clonal heterogeneity was detected for the majority of these patient samples. However, for each 
of these patients the clonal heterogeneity was reflected in the basal expression of only one or a few of 
the 18 investigated pathway mediators, i.e., this heterogeneity was not associated with a difference 
in activation status throughout the pathway. A possible explanation for this limited pathway 
heterogeneity could be that the activation status of each mediator not only reflects the downstream 
signaling from receptor ligation, but also the crosstalk between specific mediators of the PI3K-Akt-
mTOR pathway and neighboring intracellular pathways. 
Most of our patients were elderly or unfit patients that could not receive intensive antileukemic 
treatment. Our patients are thus representative with regard to AML cell biology, but they are 
heterogeneous with regard to antileukemic treatment and the elderly/unfit patients usually received 
only disease-stabilizing or supportive treatment [12]. 
Aberrant expression of lymphoid markers is relatively common in AML, and according to the 
World Health Organization (WHO) classification an uncommon subset of acute leukemia patients 
also shows a mixed phenotype with both myeloid and lymphoid leukemic cell subpopulation [1]. 
However, among our heterogeneous AML cell populations neither patients with mixed leukemic 
phenotype nor aberrant expression of lymphoid markers (CD2, CD3, CD4, CD8, CD19, CD20) were 
detected. Furthermore, the presence of clonal heterogeneity in the PI3K-Akt-mTOR pathway showed 
no association with cytogenetic abnormalities, mutational status, morphological or molecular signs 
of differentiation. Thus, our identification of two patient subsets with and without clonal 
heterogeneity based on pathway activation seems independent of the conventional subclassification 
of AML patients. 
Clonal heterogeneity can be detected by various methodological strategies [7,9,10], including 
karyotyping which identified 15% of patients with clonal heterogeneity [9]. We observed clonal 
heterogeneity for 49 out of 114 patients (42%) using our flow cytometric approach and this higher 
frequency is most likely due to an additional molecular heterogeneity not reflected by karyotyping.  
We used flow cytometry to evaluate constitutive PI3K-Akt-mTOR activation and the criteria for 
detection of two AML cell subpopulations were (i) two distinct and clearly separated cell subsets for 
one or more of the 18 mediators; and (ii) the smallest subpopulation being at least 20% of the total 
viable cell population. Considering the limited number of metaphases analyzed by karyotyping, the 
study by Bochtler et al. [9] suggests that the clonal heterogeneity has to reach a certain (i.e., detectable) 
level to have a prognostic impact. By using 20% as our cutoff it was possible to identify distinct cell 
populations, and this cutoff has also been used to define positivity for differentiation markers by flow 
cytometry [16]. 
PI3K-Akt-mTOR is a part of a complex signaling network involving several single mediators 
and showing crosstalk with other pathways [13]. We selected 18 flow cytometric parameters that 
reflect the status of the main track of the pathway, including absolute levels and phosphorylation 
status of important upstream mediators, the key mediators Akt and mTOR and mediators 
downstream to mTOR (Table S1). It can be argued that for example phosphorylated PTEN should 
also be included, even though this mediator may be less important in AML than in many other 
malignancies at least with regard to PTEN mutations; PTEN seems to be mutated in less than 1% of 
AML patients. However, PDK1 is located between PI3K and Akt in the main pathway track, and the 
activity of PTEN will be reflected in the immediately downstream PDK1 phosphorylation [4]. 
The viability of the cryopreserved cells after thawing was determined for all patients and despite 
a variation between patients, all samples showed more than 50% viable cells. One would expect less 
than 100% viability for most patients when testing cryopreserved cells [17] and the viability did not 
differ between patients with and without detectable subclones. Thus, the detection of subclones is 
not associated with altered susceptibility of the AML cells to stress-induced or spontaneous in vitro 
apoptosis. 
The AML cell population from a single patient may consist of various subclones [7,9] that can be 
detected by single cell analyses (i.e., flow cytometry) of constitutive pathway activation [10]. We 
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never observed more than two subsets (dual populations) in a patient sample, independently of 
which mediator was analyzed. However, our methodological approach does not allow an accurate 
estimation of the total number of subpopulations when dual populations were detected for two or 
more pathway mediators because the same two subpopulations may be detected when analyzing 
various pathway mediators, or different subpopulations identified by different mediators. For this 
reason, we could classify our patients as either showing or not showing clonal heterogeneity, but we 
could not estimate the number of subclones in this assay. 
We compared the global gene expression profiles for AML cell samples with and without clonal 
heterogeneity; gene expression data were then available only for an unselected subset of our patients. 
We first investigated whether gene expression profiling could be used to identify patients with and 
without detectable clonal heterogeneity in the flow cytometric analysis. AML is a very heterogeneous 
disease [12], and as would be expected the patient heterogeneity is also illustrated by the clinical and 
biological characteristics (Tables 1 and 2, Table S2) of the patients included in our present study. We 
performed a clustering analysis (Figure 2) based on the differentially expressed genes and identified 
two patient subsets corresponding to the patient samples with and without dual subpopulations. 
Thus, despite the extensive heterogeneity of the AML disease, the patient subsets that are showing 
dual populations can be identified by analysis of gene expression profiles. 
To further investigate the biological differences between patients with and without clonal 
heterogeneity, we performed a GO term analysis, and we then identified the terms with FDR <0.05 
and statistical significance with p <0.05. This analysis was based on a correction for multiple 
hypothesis testing and ontologies including few genes were left out. We identified only two GO-
terms both when the analysis was based on Biological processes (G-protein receptor signaling, 
Detection of stimulus smell) and on Molecular function (G-protein receptor activity, Olfactory 
receptor activity). 
Our present studies showed that patients with and without clonal heterogeneity differed with 
regard to the expression of genes encoding olfactory receptor components and proteins involved in 
downstream signaling from G-protein coupled receptors (GPCRs) signaling. The olfactory receptors 
are a subset of the GPCRs [18–20]. Olfactory receptors are expressed in many tissues and by many 
different normal cells outside the olfactory system. This includes several normal leukocytes (e.g., 
monocytes, neutrophil granulocytes, erythrocytes, T and B cells, NK cells) [21] as well as adipose 
tissue, heart, skeletal muscles, kidney, prostate, gastrointestinal tract, liver, lung, several endocrine 
organs, ovary and testes [22]. It can also be expressed by various malignant cells [23–28], including 
human AML cells [29,30]. Thus, both normal and malignant myeloid cells are among the cells that 
show ectopic expression of olfactory receptors, but to the best of our knowledge, our present study 
is the first to describe an association between olfactory receptor expression and prognosis in a 
hematological malignancy. Furthermore, within these tissues certain olfactory receptors seem to have 
a more limited expression, whereas other receptors have a more widespread expression [22]. Limited 
data are available for the functional roles of ectopic olfactory receptors, but the overall data suggest 
that they can be involved in modulation and regulation of important cellular processes like cell 
survival/apoptosis induction, cell-cell recognition, proliferation and migration [22,28]. For cancer 
cells, these receptors seem to influence migration and development of metastases from solid tumors 
[31–34]. Our present study is one of the first to describe the broad olfactory receptor expression by 
primary human AML cells, and to the best of our knowledge, it is the first to suggest an association 
between chemosensitivity/survival in a hematological malignancy. 
Ectopically expressed olfactory receptors influence signaling through several signal 
transduction pathways, including the PI3K-Akt-mTOR pathway as well as NFκB, MEK-ERK1/2 and 
p42/44, and they seem to regulate calcium metabolism [22]. Several of these pathways are also 
important in AML [35]. The bone marrow ligands of these receptors are not known, but one 
possibility is binding of various metabolites [36]. Several metabolites and metabolic intermediates are 
ligands for olfactory receptors, including lactate, short- and medium-chain fatty acids, ketones and 
steroids [22,28,37]. Other metabolic intermediates share structural similarities with known ligands 
[22,28]. Our hypothesis is that the ectopic olfactory receptors function as metabolic sensors and the 
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metabolic/metabolite profile of the bone marrow microenvironment thereby becomes important for 
leukemogenesis and/or AML cell chemosensitivity. The local metabolic profile will probably also be 
influenced by the systemic metabolic profile, and this may explain why differences in the systemic 
(i.e., serum) metabolite profile has a prognostic impact in human AML [38]. Finally, these receptors 
can also be expressed by various stem cells [39], but their expression at the protein level has not been 
characterized, and it is not known whether they are expressed by leukemic or normal hematopoietic 
stem cells either. However, the observation that ectopic olfactory receptors are expressed at all stages 
of erythroid cell development [28,40] suggests that they have a more widespread expression at least 
in normal hematopoietic cells. 
Clonal heterogeneity detected by cytogenetic analysis has an adverse prognostic impact [9]. We 
used a methodological approach that enabled us to investigate all patients with respect to clonal 
heterogeneity, including the large group of patients with normal karyotype and the same single 
abnormality in all investigated AML cells. Our present analysis also showed an association between 
clonal heterogeneity and adverse prognosis, and clonal heterogeneity was an independent prognostic 
parameter in our present study of a patient cohort mainly including patients with normal karyotype 
or favorable genetic abnormalities and only a small subset of patients having a complex karyotype. 
Karyotyping is not suitable for rapid detection of clonal heterogeneity in routine clinical practice 
and this methodological strategy cannot be used for the majority of patients, e.g., patients with single 
abnormalities or normal karyotype, whereas our present strategy based on flow cytometry can detect 
clonal heterogeneity within a few hours. Our present study identifies detection of heterogeneity in 
PI3K-Akt-mTOR activation as a possible biomarker with prognostic impact in human AML. 
However, the activation status of this pathway may not only be used as a biomarker; the pathway is 
involved in several important cellular functions and therefore it may be a possible therapeutic target 
in human AML. 
4. Materials and Methods  
4.1. AML Patients  
The study was approved by the Regional Ethics Committee (REK) (REK III 060.02, 10 June 2002; 
REK Vest 215.03, 12 March 2004; REK III 231.06, 15 March 2007; REK Vest 2013/634, 19 March 2013; 
REK Vest 2015/1410, 19 June 2015), The Norwegian Data Protection Authority 02/1118-5, 22 October 
2002, and The Norwegian Ministry of Health 03/05340 HRA/ASD, 16 February 2004. All AML cell 
samples were collected after written informed consent. The clinical and biological characteristics of 
the 114 unselected patients included in the study are summarized in Table 2 (49 females and 65 males; 
median age 67 years with range 18–87 years). All patients had a high number and/or percentage of 
peripheral blood blasts; leukemic peripheral blood mononuclear cells could therefore be isolated by 
density gradient separation alone (Lymphoprep, Axis-Shield, Oslo, Norway) and generally contained 
at least 95% leukemic blasts. The contaminating cells were small lymphocytes. These enriched AML 
cells were stored in liquid nitrogen until used in the experiments [41]. 
4.2. Flow-Cytometric Analysis of PI3K-Akt-mTOR Activation 
Pathway-associated clonal heterogeneity was defined as flow-cytometric detection of at least 
one extra cell population including at least 20% of the leukemic cells and being detection by the 
analysis of at least one of the PI3K-Akt-mTOR mediators. 
Flow cytometry was used to examine the constitutive expression of 18 mediators in the PI3K-
Akt-mTOR pathway/network in the AML cells. Cryopreserved and thawed primary leukemic cells 
were incubated for 20 minutes in RPMI-1640 (Sigma-Aldrich, St. Louis, MO, USA) before being 
directly fixed in 1.5% paraformaldehyde (PFA) and permeabilized with 100% ice-cold methanol. The 
cells were thereafter rehydrated by adding 2 ml phosphate-buffered saline (PBS), gently re-
suspended and then centrifuged. The cell pellet was washed twice with 2 mL PBS and resuspended 
in 150 μL PBS supplemented with 0.1% bovine serum albumin (BSA) (Sigma, St. Louis, MO, USA). 
Washed cells were blocked with immunoglobulin (Octagam; Octapharma, Jessheim, Norway) and 
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1% BSA, and thereafter split evenly into nineteen new tubes (1 × 105 cells per sample) before staining. 
All staining panels included the same live/dead discriminator, either FITC or Alexa Fluor® 647 Mouse 
anti-Cleaved PARP (Asp214); a blank sample was also included. Three directly conjugated dyes were 
used (Table S4): (i) Alexa Fluor® 647 was used for PTEN, PDPK1 (pS241), PKCα, PKCα (pT497), Akt 
(pS473), 4EBP1 (pT36/pT45), elF4E (pS209), S6 (pS244), and mTOR; (ii) phycoerythrin (PE) for Akt 
total, Akt (pT308), mTOR (pS2448), and S6 (pS240); and (iii) V450 for S6 (pS235/pS236). Antibodies 
were purchased from BD Pharmingen (Franklin Lakes, NJ, USA) except for anti-mTOR that was 
purchased from Cell Signal Technology (Danvers, MA, USA). Four of the antibodies were 
unconjugated (anti Raptor, Tuberin, FKBP38, and RHEB; all from Abcam; Cambridge, UK) and 
required secondary antibody-conjugated Alexa Fluor® 647 (Franklin Lakes, NJ, USA). Together all 
these mediators represent main steps in the PI3K-Akt-mTOR pathway and they were selected to 
provide an extended phosphorylation profile of this pathway. 
Viable leukemic cells were identified and analyzed in flow cytometric analysis based on 
live/dead staining, doublet discrimination, CD45 staining and forward/side scatter. Dead cells, 
doublets and the minor contaminating lymphocyte populations were excluded from further analyses. 
Our flow cytometric analyses were thus based on the analysis of viable leukemic cells, and the gating 
strategy used to identify the viable cell population is shown in Figure S2. 
AML cells were also incubated with human insulin 10 μg/mL (Sigma-Aldrich, St. Louis, MO, 
USA); the non-specific mTOR inhibitor rapamycin (LC Laboratories, Woburn, MA, USA) and the 
PI3K class I specific inhibitor GDC-0941 (Axon Medchem BV, Groningen, Netherlands) were added 
at a final concentration of 100 nM. Cells were incubated with these agents for 15 minutes before 
fixation/staining and flow cytometric analysis as described above. 
4.3. Analysis of Global Gene Expression Profiles and Mutation Analyses 
Our methods for RNA preparation, labelling and microarray hybridization have been described 
in detail previously [42]. All microarray experiments were performed using the Illumina iScan 
Reader, which is based upon fluorescence detection of biotin-labelled cRNA that was hybridized to 
the HumanHT-12 V4 Expression BeadChip according to the manufacturer’s instructions. The 
HumanHT-12 V4 BeadChip targets 47 231 probes that are mainly derived from genes in the NCBI 
RefSeq database (Release 38). Preprocessing, normalization and annotations of the microarray data 
has also been described in detail in this previous publication; the data from the array scanning were 
investigated in GenomeStudio and J-Express 2012 for quality control measures. 
Submicroscopic mutation profiling of 54 genes frequently mutated in myeloid leukemias was 
done using the Illuminas TruSight Myeloid Gene Panel and sequenced using the MiSeq system and 
reagent kit v3 (all from Illumina, San Diego, CA, USA) as described in detail previously [42]. The 
methods for fragment analysis of Flt3 exon 14–15 and NPM1 exon 12 and analysis of CEBPA 
mutations have also been described previously [42]. 
4.4. Data Collection, Bioinformatical and Statistical Analyses 
Flow cytometry analysis was acquired on a BD FACSVerse 8-color flow cytometer (BD 
Biosciences; Franklin Lakes, NJ, USA) and data analysis performed using FlowJo 10.0.7 software (Tree 
Star, Inc., Ashland, OR, USA). The J-Express software (J-Express 2012, MolMine AS, Bergen, Norway) 
was used for bioinformatical analyses. For unsupervised hierarchical clustering analysis, all values 
were calculated using fold change on the Inverse hyperbolic sine (Arcsinh) scale and with median 
values for each target group as control. Complete linkage (euclidean distance) and Pearson 
correlation were used as linkage method and distance measurement, respectively. Statistical analyses 
were performed using the IBM Statistical Package for the Social Sciences (SPSS) version 23 (IBM 
Corporation, Armonk, NY, USA). The Mann-Whitney U-test was used to compare different groups; 
the Chi square/Fischer’s exact test for analysis of categorized data and the Kendall’s tau-b correlation 
test for correlation analyses. The Cox Proportional Hazard Model was used for analysis of survival 
data. p-values <0.05 were regarded as statistically significant. The gene ontology enrichment analysis 
of differentially expressed genes was performed by using online bioinformatics tools of DAVID 
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Bioinformatics Resources 6.8, Laboratory of Human Retrovirology and Immunoinformatics (LHRI) 
[43,44]. 
5. Conclusions 
To conclude, clonal heterogeneity in human AML cell samples is reflected in the activation of 
mediator in the PI3K-Akt-mTOR pathway, and this heterogeneity had an independent prognostic 
impact in our patient cohort. Our present study suggests that that clonal heterogeneity as reflected 
in intracellular signaling pathways should be further investigated as a possible adverse prognostic 
biomarker in future clinical studies. 
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